Table 3.

Clinical outcomes.

	Diabetes Patients N = 72	Non-Diabetes Patients N = 121	p-Value
30-Day FU Primary outcome: cardiac death, myocardial infarction, stent thrombosis	0 (0%)	0 (0%)	-
30-Day FU Principal secondary outcome: Target lesion failure (cardiac death, target vessel myocardial infract, target lesion-revascularization)	0 (0%)	0 (0%)	-
30-Day FU Death:
-Any death	0 (0%)	0 (0%)	-
-Cardiac death	0 (0%)	0 (0%)	-
30-Day FU Myocardial infraction:
-Any MI	0 (0%)	0 (0%)	-
-Target vessel myocardial infract	0 (0%)	0 (0%)	-
30-Day FU Scaffold thrombosis	0 (0%)	0 (0%)	-
Scaffold restenosis	0 (0%)	0 (0%)	-
30-Day FU Stroke	0 (0%)	0 (0%)	-
TIA	0 (0%)	0 (0%)	-
30-Day FU Revascularization:
-Target lesion revascularization	0 (0%)	0 (0%)	-
-Target vessel revascularization	0 (0%)	0 (0%)	-
-Any revascularization	0 (0%)	0 (0%)	-
1-Year FU Primary outcome: cardiac death, myocardial infarction, stent thrombosis	2 (2.7%)	1 (0.8%)	p = 0.557
1-Year FU Principal secondary outcome: Target lesion failure (cardiac death, target vessel myocardial infract, target lesion-revascularization)	3 (4.1%)	0 (0%)	p = 0.051
1-Year FU Death
-Any death	2 (2.7%)	0(0%)	p = 0.138
-Cardiac death	0 (0%)	0(0%)	-
1-Year FU Myocardial infraction:
-Any MI	2 (2.7%)	1 (0.8%)	p = 0.557
-Target vessel myocardial infract	2 (1.3%)	0 (0%)	p = 0.138
1-Year FU Scaffold thrombosis	0 (0%)	0 (0%)	-
Scaffold restenosis	2 (2.7%)	0 (0%)	p = 0.138
1-Year FU Stroke	2 (2.7%)	0 (0%)	p = 0.138
TIA	0 (0%)	1 (0.8%)	p > 0.999
1-Year FU Revascularization:
-Target lesion revascularization	2 (2.7%)	0 (0%)	p = 0.138
-Target vessel revascularization	3 (2.7%)	0 (0%)	p = 0.051
-Any revascularization	10 (13.8%)	8 (6.6%)	p = 0.124

Abbreviations: TIA—transient ischemic attack; PCI—percutaneous coronary intervention; ASA—acetylsalicylic acid; MI—myocardial infraction.